Autoimmune Drugs Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Autoimmune Drugs Market Trends and Insights

Rising Prevalence and Earlier Diagnosis of Autoimmune Diseases

Earlier patient identification supports the autoimmune drugs market, driven by improved biomarker panels, point-of-care serology tests, and integrated electronic health records. A 2024 analysis using Global Burden of Disease 2024 data found rising incidence trends for rheumatoid arthritis, multiple sclerosis, and type 1 diabetes among people aged 15-39 years from 1990 to 2024, with prevalence projected to continue rising through 2032.^{[1]Hari Krishnamurthy et al., “Estimation of Prevalence of Autoimmune Diseases in the United States Using Electronic Health Record Data,” Journal of Clinical Investigation, doi.org} A 2025 study across six major U.S. health systems identified more than 15 million Americans diagnosed with at least one of 105 autoimmune conditions, and 34% of diagnosed patients had more than one autoimmune condition. Earlier diagnosis in primary care supports timely treatment before severe complications, favoring therapies that address multiple inflammatory conditions or adapt to changing patient care needs.

Expansion of Biologic and Targeted Synthetic Therapies

Biologic and targeted synthetic therapies remain key value drivers in the autoimmune drugs market, especially for patients not adequately controlled with conventional treatment. Emerging approaches include BTK inhibitors for multiple sclerosis, FcRn inhibitors for IgG-mediated conditions, and later-stage cell therapies for severe autoimmune diseases. These programs are shifting competition beyond established TNF and IL-12/23 mechanisms toward specialized pathways. Generic tofacitinib tablets launched in the United States in June 2026, increasing price pressure on an earlier oral targeted therapy and making differentiated clinical profiles, convenient administration, broader labels, biomarker-led patient selection, and self-administered formats more important.

Increasing Treatment Adoption in Emerging Markets

Expanding biologics production and clinical development capacity in Asia-Pacific is supporting the autoimmune drugs market. India’s biotechnology sector increased from USD 10 billion in 2014 to USD 130 billion in 2024, strengthening the country’s manufacturing and clinical research base. China’s National Medical Products Administration introduced a 30-day investigational new drug fast-track process in 2025, shortening entry timelines for domestic and multinational development programs. Broader manufacturing capacity, regulatory cooperation, and multi-country approvals can improve access to biologics and biosimilars and help South Korean and Indian producers serve multiple markets with the same portfolio.

Expansion of Indications for Established Immunology Products

Label expansion remains a practical strategy for established immunology products to extend their role across disease areas and patient groups. AbbVie’s Rinvoq received its ninth U.S. approval for giant cell arteritis in 2025, and the company filed for non-segmental vitiligo, with an FDA decision expected in the fourth quarter of 2026. Johnson & Johnson received FDA approval for Stelara in pediatric Crohn’s disease for patients aged 2 years and older in April 2026. Sanofi and Regeneron received FDA approval for Dupixent in children aged 2-11 years with chronic spontaneous urticaria in April 2026, creating new treatment options while supporting branded therapy relevance as biosimilars compete in older adult indications.

High Cost of Biologic Development and Long Clinical Timelines

Developing a new biologic requires lengthy clinical programs, complex trial designs, and extensive safety monitoring. These requirements become more demanding when sponsors study narrowly defined patient groups or use adaptive trial designs. Sanofi’s tolebrutinib was not approved by the FDA for non-relapsing secondary progressive multiple sclerosis in December 2025, despite positive HERCULES Phase 3 results, due to concerns over severe drug-induced liver injury. The European Commission approved the medicine as Cenrifki in June 2026 for the same condition, highlighting regulatory variation across markets and increasing the financial risk of parallel global development programs.

Biosimilar Competition and Loss of Exclusivity

Biosimilars are shifting revenue from originator biologics to lower-cost alternatives, particularly in established TNF inhibitor classes. In May 2026, the FDA approved IMMGOLIS and IMMGOLIS INTRI, the first biosimilars to Simponi and Simponi Aria. Infliximab biosimilars controlled 51% of market volume, indicating that mature classes can transition rapidly once several alternatives become available. Price competition can expand treatment access but reduce revenue growth for originators and suppliers, while interchangeability and biosimilar development requirements continue to create meaningful costs for smaller entrants.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug Class: NSAIDs Retain Broad Use While Corticosteroids Gain New Roles

NSAIDs held 34.56% of segment revenue in 2025, supported by broad use across rheumatoid arthritis, ankylosing spondylitis, lupus, and psoriatic arthritis. Their affordability and familiar safety profile support routine prescribing, although they do not modify the underlying disease course. Conventional synthetic DMARDs, including methotrexate and hydroxychloroquine, remain key first-line options for rheumatoid arthritis, especially in markets where reimbursement limits or out-of-pocket costs restrict biologic access. Biologic DMARDs and targeted synthetic DMARDs contribute significant value, with U.S. annual prices ranging from USD 15,000 to USD 60,000 per patient, while interferons retain an established role in multiple sclerosis.

Corticosteroids recorded the highest projected growth rate among drug classes, at a 9.15% CAGR from 2026 to 2031. Their use is expanding in induction combinations, bridging strategies, and regimens that require low-dose support while a biologic takes effect. European guidance increasingly treats dosing as a precision decision rather than applying broad avoidance. Immunosuppressants, intravenous immunoglobulin, FcRn inhibitors, S1P receptor modulators, and pipeline agents targeting APRIL, BAFF, and complement pathways continue to broaden the autoimmune drugs market beyond conventional inflammatory control.

By Disease Indication: Rheumatoid Arthritis Leads While Multiple Sclerosis Expands Fastest

Rheumatoid arthritis accounted for 46.93% of indication revenue in 2025, driven by a large patient base, high treatment intensity, and frequent use of combination therapy. Conventional DMARDs, biologics, and targeted therapies each support treatment as disease severity or response changes. Psoriatic arthritis, psoriasis, and atopic dermatitis form a large treatment cluster, where IL-17, IL-23, and IL-4/13 therapies compete for prescriber preference. Inflammatory bowel disease remains a high-spend area, with Crohn’s disease and ulcerative colitis supporting demand for agents such as vedolizumab and risankizumab, while ankylosing spondylitis, axial spondyloarthritis, and other indications remain stable contributors.

Multiple sclerosis is forecast to grow at an 8.80% CAGR from 2026 to 2031, the fastest rate among disease indications. The European Commission approved Sanofi’s Cenrifki in June 2026 for secondary progressive multiple sclerosis without relapses, adding a new option for smoldering neuroinflammation. This development could shift prescribing toward CNS-penetrant BTK inhibitors and away from older first-line therapies for relevant patients. The U.S. launch of Tyruko, the first natalizumab biosimilar, in November 2025 increased competitive pressure in multiple sclerosis, while FDA approval of Benlysta autoinjector for pediatric lupus nephritis patients aged 5 years and older in June 2025 broadened access in an underpenetrated indication.

By Route of Administration: Oral Products Lead While Intravenous Delivery Serves Complex Disease

Oral products held 61.45% of the autoimmune drugs market size in 2025, supported by high prescription volumes for NSAIDs, conventional DMARDs, JAK inhibitors, and S1P receptor modulators. Methotrexate, hydroxychloroquine, and leflunomide remain widely used oral treatments across several autoimmune conditions. Oral administration is important in maintenance treatment, where patients need familiar and convenient regimens. AbbVie reported USD 8.304 billion in 2025 revenue for Rinvoq, while the launch of generic tofacitinib in June 2026 added price competition in the oral targeted category.

Intravenous delivery is forecast to grow at a 7.45% CAGR from 2026 to 2031. It remains important for severe lupus nephritis, neuromyelitis optica, multiple sclerosis, and complex rheumatoid arthritis, where clinical supervision supports adherence and monitoring. Ambulatory infusion centers and home infusion programs are expanding the settings for intravenous biologic delivery. FDA guidance on home infusion safety and CMS reimbursement policy remain important factors shaping adoption, as the autoimmune drugs market benefits from closer-to-home access without compromising monitoring.

By Formulation: Tablets and Capsules Lead While Prefilled Syringes Expand

Tablets and capsules held a 45.78% share of the autoimmune drugs market in 2025 because orally administered NSAIDs, conventional DMARDs, and small-molecule therapies remain widely prescribed. These formats support patient familiarity and long-term maintenance treatment. Vials and ampoules remain important in hospital pharmacies, particularly for compounding and individualized dosing. Oral solutions, suspensions, and auto-injector pens address pediatric, older-patient, localized, and self-administration needs.

Prefilled syringes are forecast to grow at an 8.56% CAGR from 2026 to 2031. The biologic and biosimilar pipeline increasingly favors subcutaneous self-administration to support adherence and lower administration costs. AbbVie received FDA approval in June 2026 for a 55 mg prefilled syringe for Skyrizi, designed for weight-based pediatric dosing in patients under 40 kg. Auto-injector pens are also being refined for patient comfort, needle concealment, and connected adherence support, helping preserve patient and provider preference where biosimilar alternatives are available.

By End User: Hospitals Lead While Adolescent Care Gains Momentum

Hospitals accounted for a 52.67% share of the autoimmune drugs market in 2025. They remain the main sites for intravenous biologic initiation, complex induction regimens, and care for patients with severe or multi-system disease. Formulary committee decisions strongly influence access to new biologics across large purchasing networks. Specialty clinics, ambulatory infusion centers, physician offices, and home healthcare settings are gaining relevance as ongoing monitoring and self-injected therapies expand.

The adolescent patient cohort aged 12-17 years is forecast to grow at an 8.55% CAGR from 2026 to 2031. Pediatric label expansions between 2025 and 2026 included Tremfya for pediatric psoriasis and psoriatic arthritis, Yuflyma for adolescent hidradenitis suppurativa, and Cosentyx for patients aged 12 years and older with hidradenitis suppurativa. Skyrizi was approved for pediatric psoriatic disease in June 2026, and Tzield received accelerated FDA approval for children aged 8-17 years with stage 3 type 1 diabetes in June 2026. These actions are increasing the need for pediatric specialist capacity, payer coverage, and patient support services, while Pediatric Research Equity Act requirements encourage evidence development for younger populations.

Geography Analysis

North America held 38.67% of regional revenue in 2025, supported by high treatment rates, broad biologic reimbursement, and strong immunology research activity. The United States remained a key center of biosimilar-led price disruption. Ustekinumab biosimilars reached a 42% U.S. share in the first quarter of 2026, while infliximab biosimilars controlled 51% of market volume. These shifts lowered originator pricing pressure and expanded patient access, while Canada’s formulary expansions and Mexico’s hospital modernization supported regional demand.

AbbVie expected Skyrizi and Rinvoq to generate USD 34.5 billion in combined revenue in 2026, within total company sales guidance of USD 67 billion. Europe was the second-largest regional contributor, with Germany, the United Kingdom, France, Italy, and Spain accounting for much of the region’s autoimmune therapy revenue. The European Commission’s approval of Cenrifki in June 2026 indicated continued regulatory support for therapies addressing progressive neurological autoimmune disease. German reference-pricing processes reduced launch-year pricing leverage for newer biologics, while higher-income Central and Eastern European markets increased biologic use.

Asia-Pacific is forecast to grow at a 9.58% CAGR from 2026 to 2031, making it the fastest-growing regional part of the autoimmune drugs market. Manufacturing capacity, clinical infrastructure, and biosimilar development expanded across China, India, and South Korea. India’s biotechnology expansion supported its role as a biosimilar exporter and clinical trial destination. Middle East and Africa and South America remained smaller contributors, although Gulf countries, Brazil, and Argentina increased specialty-care investment and public procurement for autoimmune treatment.